Efficacy and Safety of Xuebijing Injection in the Treatment of Septic Cardiomyopathy: Protocol for a Systematic Review and Meta-analysis
Abstract
Background: This protocol describes the planned evaluation of the efficacy and safety of Xuebijing injection (XBJI) as adjunctive therapy for septic cardiomyopathy (SCM). Materials and Methods: Eight databases will be searched from January 1, 2000 to October 1, 2026 to identify randomized controlled trials of XBJI plus conventional Western therapy for SCM. Risk of bias will be assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2). Review Manager Web (RevMan Web; Cochrane, London, UK) will be used for meta-analysis. Subgroup analysis, sensitivity analysis, publication bias assessment, trial sequential analysis, and certainty-of-evidence assessment using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach are prespecified. The primary outcomes are creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI). Secondary outcomes include B-type natriuretic peptide (BNP), lactate dehydrogenase (LDH), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), procalcitonin (PCT), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, intensive care unit length of stay, 28-day mortality, echocardiographic indices of cardiac function, and adverse events. Discussion: This protocol was designed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines to synthesize the available evidence on XBJI as adjunctive treatment for SCM. The findings will be reported after completion of the systematic review and meta-analysis.
References
Beesley SJ, Weber G, Sarge T, Nikravan S, Grissom CK, Lanspa MJ, et al. Septic cardiomyopathy. Crit Care Med. 2018;46(4):625-34.
https://doi.org/10.1097/CCM.0000000000002851
PMid:29227368
Carbone F, Liberale L, Preda A, Schindler TH, Montecucco F. Septic cardiomyopathy: from pathophysiology to the clinical setting. Cells. 2022;11(18):2833.
https://doi.org/10.3390/cells11182833
PMid:36139408 PMCid:PMC9496713
Wu J, Wang L, Hu Y, Yu X, Tao R, Liu T. Clinical effect of Shenfu injection combined with Shenmai injection in the treatment of sepsis-induced myocardial dysfunction. Clin Res Pract. 2022;7(26):111-3.
Yin Y. The epidemiological investigation of sepsis, sepsis-induced myocardial dysfunction (SIMD) in intensive care unit of tertiary hospitals in Hebei Province [master's thesis]. Shijiazhuang: Hebei Medical University; 2017.
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-247.
https://doi.org/10.1007/s00134-021-06506-y
PMid:34599691
Hu Q, Cao X, Huang Z, Xie M, Yu R, Wang J. The pathogenesis and treatment of septic cardiomyopathy. West China Med J. 2020;35(11):1380-5.
Liao Y, Lu J, Wang Z, Xu Q. Clinical research of Xuebijing injection on myocardial protection from sepsis. China Med Pharm. 2020;10(22):55-7.
Li X, Chen Y. Clinical observation on the treatment of sepsis induced myocardial injury with Xuebijing injection. J Emerg Tradit Chin Med. 2016;25(8):1582-4.
Wu H. The effect of Xuebijing injection combined with ambroxol hydrochloride injection in the treatment of severe pneumonia and its impact on lung function. Chin J Clin Ration Drug Use.2024;17(4):63-6.
Wu J, Liu X. Research progress on the anti-inflammatory mechanism of Xuebijing injection. Lab Med Clin. 2013;10(15):2030-2.
Lu H, Fan L. Evidence based application, adverse reactions, and usage precautions of Xuebijing injection. Chin J New Drugs. 2013;22(20):2449-52.
He J, Yin X, Ma S, Guo L, Zhang M. The effects of Xuebijing injection on cardiac function and endothelial function in rats with sepsis. Chin J Integr Med Cardio-Cerebrovasc Dis. 2017;15(14):1710-5.
Wang X. Study on pharmacodynamic substance basis and mechanism of Xuebijing injection in preventing heart dysfunction in septic mice [master's thesis]. Tianjin: Tianjin University of Traditional Chinese Medicine; 2022.
Wen H, Yan S, Yuan L, Yu T, Gu X, Jiang Y, et al. Mechanism of Xuebijing injection exerted to improve the metabolic disturbance induced by early sepsis based on the metabonomics approach. Chin J Clin Pharmacol. 2023;39(18):2679-83.
Zhou G, He B, Ye L, Zhang L, Ma L, Gao L, et al. Meta-analysis of the efficacy of Xuebijing combined with Ulinastatin in the treatment of sepsis. J Guangdong Med Univ. 2014;32(5):626-8.
Zhou X, Tang G, Li J, Ye Y. A systematic evaluation of Xuebijing in reducing mortality in patients with septic shock. Chin Arch Tradit Chin Med. 2016;34(9):2161-4.
Li J, Shao X, Xie N, Lu J, Wei J, Fan K. Meta-analysis of the efficacy and safety of Xuebijing injection in the treatment of sepsis with cardiac dysfunction. J Emerg Tradit Chin Med. 2023;32(2):189-94.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
https://doi.org/10.1186/1471-2288-14-135
PMid:25524443
Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785-805.
https://doi.org/10.1177/0962280216669183
PMid:27683581 PMCid:PMC7704078
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
Weng H, Li S, Zeng XT, Wu SS, Liu Q, Wang XH. Application of the trial sequential analysis software for meta-analysis. Chin J Evid-Based Med. 2016;16(5):604-11.
Cai Z. Analysis of the mechanism of action of "Fuzi Guizhi Fuling" angle medicine in the treatment of chronic heart failure based on network pharmacology [master's thesis]. Nanning: Guangxi University of Chinese Medicine; 2023.
Wang C. The clinical pharmacological effects of using traditional Chinese medicine Huangqi in the treatment of cardiovascular diseases. Fertility and Health. 2023;29(1):64-6.
Gu X. Analysis of the rational use of traditional Chinese medicine preparations in the treatment of cardiovascular diseases. Cardiovasc Dis Electron J Integr Tradit Chin West Med. 2018;6(34):16.
Zhang N. The role and mechanism of Atg7 in septic cardiomyopathy [master's thesis]. Wuhan: Wuhan University; 2022.
Zhu S, Huang Y, Zhu W, Zhang L. Clinical application and safety analysis of Xuebijing injection based on the real world. Chin J Clin Ration Drug Use. 2023;16(23):24-7.
Wang L, Zheng Y. Progress in pharmacological research on Xuebijing injection. Proc Clin Med. 2016;25(7):542-4.
Jiang W, Zhou Y, Wang Y, Chen C. Effect of Xuebijing injection on inflammatory stress response and myocardial function in patients with sepsis of EICU. Shaanxi J Tradit Chin Med. 2020;41(4):502-4.
Chen D, Zhong J, Feng Y, Wei Q, Chu M, Liu L. Clinical intervention of Xuebijing injection on myocardial dysfunction caused by sepsis. Harbin Med J. 2019;39(6):549-50.
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Galen Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
